Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8
Needham analyst Joseph Stringer initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $8.
Stocks · News reference
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference
CAMP4 Therapeutics announced its participation in a panel discussion titled 'RNA Medicines: Transcriptome Engineering' at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The panel will be held in New York and webcast live, with a 30-day replay available on CAMP4's investor relations website.
Chardan Capital Maintains Buy on Camp4 Therapeutics, Lowers Price Target to $6
Chardan Capital analyst Keay Nakae maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Buy and lowers the price target from $6.5 to $6.
8-K filing — Camp4 Therapeutics Corp (CAMP)
Filed: 2026-09-28 AccNo: 0001628280-26-063740 Size: 9 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits